GlassScriptPhysician profile
Abbas Khalil
NPI 1093716698
$2,475.14
in general payments reported to CMS, 2019-2025
28 companies · $257 in 2025
The $257 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $277 · 2020: $152 · 2021: $511 · 2022: $495 · 2023: $451 · 2024: $332 · 2025: $257.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,028 · Education: $13.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,027.50 |
| Education | $13.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $332.42 | 2019-2025 | Opdivo |
| Novartis Pharmaceuticals Corporation | $273.79 | 2019-2025 | |
| Janssen Biotech, INC. | $256.32 | 2019-2024 | Imbruvica, Darzalex, Rybrevant |
| Aveo Pharmaceuticals, INC. | $167.37 | 2021-2024 | Fotivda |
| Amgen INC. | $160.02 | 2019-2023 | Kyprolis, Blincyto |
| Pfizer INC. | $153.95 | 2019-2025 | |
| Celgene Corporation | $152.98 | 2022-2023 | Pomalyst, Orencia, Opdualag |
| Abbvie INC. | $143.64 | 2024-2025 | |
| Glaxosmithkline, LLC. | $133.37 | 2021-2025 | Jemperli, Zejula, Ojjaara |
| Servier Pharmaceuticals LLC | $113.25 | 2021-2023 | |
| Coherus Oncology, INC. | $104.39 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $101.13 | 2019-2024 | Keytruda, Reblozyl, Welireg |
| Pharmacyclics LLC, An Abbvie Company | $84.61 | 2022-2023 | Epkinly |
| Genzyme Corporation | $44.90 | 2020-2024 | |
| Lilly USA, LLC | $38.86 | 2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $24.04 | 2024 | |
| Shield Therapeutics INC | $22.63 | 2025 | |
| Daiichi Sankyo INC. | $21.26 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.84 | 2021 | |
| Astellas Pharma US INC | $16.89 | 2025 | Padcev |
| Morphosys, US INC. | $16.62 | 2021 | |
| Pharmacosmos Therapeutics INC. | $15.35 | 2024 | Cosela |
| Janssen Pharmaceuticals, INC | $14.15 | 2019 | |
| Novo Nordisk INC | $13.97 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.21 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $13.08 | 2024 | Libtayo |
| Adc Therapeutics America, INC. | $12.59 | 2022 | |
| Genentech USA, INC. | $11.51 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbas Khalil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.